Rates of high-on platelet reactivity (HPR) in patients with non-ST segment elevation acute coronary syndrome were significantly lower in the short term when these patients took eptifibatide bolus and clopidogrel before percutaneous coronary intervention (PCI) than those who were given crushed ticagrelor tablets, according to findings presented Monday at Cardiovascular Research Technologies (CRT) 2018.